NASDAQ:PRME Prime Medicine (PRME) Stock Price, News & Analysis $2.98 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$2.99 +0.01 (+0.37%) As of 07:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Prime Medicine Stock (NASDAQ:PRME) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Prime Medicine alerts:Sign Up Key Stats Today's Range$2.92▼$3.0850-Day Range$2.81▼$3.7152-Week Range$2.67▼$6.94Volume2.11 million shsAverage Volume3.23 million shsMarket Capitalization$540.51 millionP/E RatioN/ADividend YieldN/APrice Target$7.47Consensus RatingModerate Buy Company Overview Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company developing genetic medicines based on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company’s platform is intended to address a broad range of genetic diseases while potentially reducing some of the limitations associated with earlier gene-editing approaches. Prime Medicine is advancing an investigational pipeline of therapies for diseases caused by genetic mutations. Its lead program, PM359, is an ex vivo gene-editing therapy being developed for chronic granulomatous disease, a rare inherited disorder that affects the immune system. The company is also researching additional applications of prime editing in hematologic, immunologic and other serious diseases. Founded in 2019 and headquartered in Cambridge, Massachusetts, Prime Medicine emerged from research associated with prime-editing pioneer David Liu and collaborators. The company’s activities are primarily focused on research, preclinical development and clinical testing of genetic medicines, with its programs intended for patients with serious inherited conditions in the United States and potentially other markets subject to regulatory approval.AI Generated. May Contain Errors. Read More Prime Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScorePRME MarketRank™: Prime Medicine scored higher than 68% of companies evaluated by MarketBeat, and ranked 230th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingPrime Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 1 strong buy rating, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPrime Medicine has a consensus price target of $7.47, representing about 150.7% upside from its current price of $2.98.Amount of Analyst CoveragePrime Medicine has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Prime Medicine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Prime Medicine are expected to grow in the coming year, from ($0.97) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prime Medicine is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prime Medicine is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPrime Medicine has a P/B Ratio of 4.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.10% of the float of Prime Medicine has been sold short.Short Interest Ratio / Days to CoverPrime Medicine has a short interest ratio ("days to cover") of 12.31, which indicates bearish sentiment.Change versus previous monthShort interest in Prime Medicine has recently decreased by 12.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPrime Medicine does not currently pay a dividend.Dividend GrowthPrime Medicine does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.32 News SentimentPrime Medicine has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Prime Medicine this week, compared to 3 articles on an average week.Search Interest9 people have searched for PRME on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows5 people have added Prime Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Prime Medicine insiders have not sold or bought any company stock.Percentage Held by Insiders16.04% of the stock of Prime Medicine is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.37% of the stock of Prime Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prime Medicine's insider trading history. Receive PRME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prime Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRME Stock News HeadlinesPrime Medicine (NASDAQ:PRME) Earns Buy Rating from Chardan CapitalSeptember 27, 2026 | americanbankingnews.comPrime Medicine Clears FDA Hurdle For Gene-Editing Therapy Targeting Rare Genetic Disease; Stock UpSeptember 26, 2026 | rttnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 5 at 1:00 AM | Banyan Hill Publishing (Ad)Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer SaysSeptember 26, 2026 | finance.yahoo.comPrime: A Buy Due To BLA Filing H1 '27 And Continued PM647 AdvancementSeptember 25, 2026 | seekingalpha.comPrime Medicine, Inc.: Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin DeficiencySeptember 25, 2026 | finanznachrichten.dePrime Medicine Shares Jump on FDA Clearance for Investigational New Drug ApplicationSeptember 24, 2026 | marketscreener.comMPrime Medicine stock surges on FDA IND clearanceSeptember 24, 2026 | finance.yahoo.comSee More Headlines PRME Stock Analysis - Frequently Asked Questions How have PRME shares performed this year? Prime Medicine's stock was trading at $3.47 at the beginning of 2026. Since then, PRME stock has decreased by 14.1% and is now trading at $2.98. How were Prime Medicine's earnings last quarter? Prime Medicine, Inc. (NASDAQ:PRME) posted its earnings results on Thursday, August, 6th. The company reported ($0.24) earnings per share for the quarter, meeting the consensus estimate of ($0.24). The firm had revenue of $1.15 million for the quarter, compared to analyst estimates of $4.40 million. Prime Medicine had a negative net margin of 4,613.11% and a negative trailing twelve-month return on equity of 188.27%. When did Prime Medicine IPO? Prime Medicine (PRME) raised $175 million in an IPO on Thursday, October 20th 2022. The company issued 10,294,118 shares at $16.00-$18.00 per share. How do I buy shares of Prime Medicine? Shares of PRME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Prime Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prime Medicine investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Intel (INTC), NVIDIA (NVDA), Meta Platforms (META) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/06/2026Today10/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PRME's financial health is in the Yellow zone, according to TradeSmith. PRME has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PRME Previous SymbolNASDAQ:PRME CIK1894562 Webprimemedicine.com Phone(617) 465-0013FaxN/AEmployees146Year Founded2019Price Target and Rating Average Price Target for Prime Medicine$7.47 High Price Target$11.00 Low Price Target$4.25 Potential Upside/Downside+150.7%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$201.14 million Net Margins-4,613.11% Pretax Margin-4,613.11% Return on Equity-188.27% Return on Assets-59.11% Debt Debt-to-Equity RatioN/A Current Ratio3.05 Quick Ratio3.05 Sales & Book Value Annual Sales$4.63 million Price / Sales116.74 Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book4.45Miscellaneous Outstanding Shares181,380,000Free Float152,284,000Market Cap$540.51 million OptionableN/A Beta2.37 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:PRME) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
